Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 252

1.

Cytokine Signaling in Tumor Progression.

Lee M, Rhee I.

Immune Netw. 2017 Aug;17(4):214-227. doi: 10.4110/in.2017.17.4.214. Epub 2017 Aug 9. Review.

2.

Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development.

Andersen M, Sajid Z, Pedersen RK, Gudmand-Hoeyer J, Ellervik C, Skov V, Kjær L, Pallisgaard N, Kruse TA, Thomassen M, Troelsen J, Hasselbalch HC, Ottesen JT.

PLoS One. 2017 Aug 31;12(8):e0183620. doi: 10.1371/journal.pone.0183620. eCollection 2017.

3.

Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.

Kong Y, Wu YL, Song Y, Shi MM, Cao XN, Zhao HY, Qin YZ, Lai YY, Jiang H, Jiang Q, Huang XJ.

J Transl Med. 2017 Aug 30;15(1):184. doi: 10.1186/s12967-017-1286-5.

4.

Deconvolution of the Response to Bacillus Calmette-Guérin Reveals NF-κB-Induced Cytokines As Autocrine Mediators of Innate Immunity.

Bisiaux A, Boussier J, Duffy D, Quintana-Murci L, Fontes M, Albert ML; Milieu Intérieur Consortium.

Front Immunol. 2017 Jul 13;8:796. doi: 10.3389/fimmu.2017.00796. eCollection 2017.

5.

Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.

Meyer SC, Steinmann E, Lehmann T, Muesser P, Passweg JR, Skoda RC, Tsakiris DA.

Biomed Res Int. 2017;2017:9876819. doi: 10.1155/2017/9876819. Epub 2017 Jun 18.

6.

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.

Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S.

Blood. 2017 Aug 31;130(9):1125-1131. doi: 10.1182/blood-2017-05-783225. Epub 2017 Jul 3.

PMID:
28674026
7.

Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.

Zick A, Peretz T, Lotem M, Hubert A, Katz D, Temper M, Rottenberg Y, Uziely B, Nechushtan H, Meirovitz A, Sonnenblick A, Sapir E, Edelman D, Goldberg Y, Lossos A, Rosenberg S, Fried I, Finklstein R, Pikarsky E, Goldshmidt H.

Medicine (Baltimore). 2017 May;96(20):e6931. doi: 10.1097/MD.0000000000006931.

8.

JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Bose P, Verstovsek S.

Blood. 2017 Jul 13;130(2):115-125. doi: 10.1182/blood-2017-04-742288. Epub 2017 May 12. Review.

PMID:
28500170
9.

Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis.

Song J, Hussaini M, Zhang H, Shao H, Qin D, Zhang X, Ma Z, Hussnain Naqvi SM, Zhang L, Moscinski LC.

Am J Clin Pathol. 2017 May 1;147(5):444-452. doi: 10.1093/ajcp/aqw222.

10.

Cellular Senescence: A Translational Perspective.

Kirkland JL, Tchkonia T.

EBioMedicine. 2017 Jul;21:21-28. doi: 10.1016/j.ebiom.2017.04.013. Epub 2017 Apr 12. Review.

11.

Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.

Lim KH, Chen CG, Chang YC, Chiang YH, Kao CW, Wang WT, Chang CY, Huang L, Lin CS, Cheng CC, Cheng HI, Su NW, Lin J, Chang YF, Chang MC, Hsieh RK, Lin HC, Kuo YY.

Oncotarget. 2017 May 16;8(20):32476-32491. doi: 10.18632/oncotarget.16381.

12.

Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.

Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, Chen IM, Valentine M, Liu Y, Li Y, Shao Y, Easton J, Payne-Turner D, Gu Z, Tran TH, Nguyen JV, Devidas M, Dai Y, Heerema NA, Carroll AJ 3rd, Raetz EA, Borowitz MJ, Wood BL, Angiolillo AL, Burke MJ, Salzer WL, Zweidler-McKay PA, Rabin KR, Carroll WL, Zhang J, Loh ML, Mullighan CG, Willman CL, Gastier-Foster JM, Hunger SP.

Blood. 2017 Jun 22;129(25):3352-3361. doi: 10.1182/blood-2016-12-758979. Epub 2017 Apr 13.

PMID:
28408464
13.

Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics.

Ember SW, Lambert QT, Berndt N, Gunawan S, Ayaz M, Tauro M, Zhu JY, Cranfill PJ, Greninger P, Lynch CC, Benes CH, Lawrence HR, Reuther GW, Lawrence NJ, Schönbrunn E.

Mol Cancer Ther. 2017 Jun;16(6):1054-1067. doi: 10.1158/1535-7163.MCT-16-0568-T. Epub 2017 Mar 23.

PMID:
28336808
14.

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

Manduzio P.

Ther Clin Risk Manag. 2017 Feb 13;13:169-177. doi: 10.2147/TCRM.S121683. eCollection 2017.

15.

JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1.

Gupta N, Edelmann B, Schnoeder TM, Saalfeld FC, Wolleschak D, Kliche S, Schraven B, Heidel FH, Fischer T.

Leukemia. 2017 May;31(5):1223-1226. doi: 10.1038/leu.2017.26. Epub 2017 Jan 18. No abstract available.

16.

Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.

Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z.

Lancet Haematol. 2017 Feb;4(2):e67-e74. doi: 10.1016/S2352-3026(16)30194-6. Epub 2017 Jan 12.

PMID:
28089238
17.

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.

Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN.

Leukemia. 2017 Sep;31(9):1951-1961. doi: 10.1038/leu.2016.393. Epub 2017 Feb 2.

18.

Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo.

Spivak AM, Larragoite ET, Coletti ML, Macedo AB, Martins LJ, Bosque A, Planelles V.

Retrovirology. 2016 Dec 20;13(1):88. doi: 10.1186/s12977-016-0319-0.

19.

Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms.

Marin Oyarzún CP, Carestia A, Lev PR, Glembotsky AC, Castro Ríos MA, Moiraghi B, Molinas FC, Marta RF, Schattner M, Heller PG.

Sci Rep. 2016 Dec 13;6:38738. doi: 10.1038/srep38738.

20.

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib.

Abidi MZ, Haque J, Varma P, Olteanu H, Guru Murthy GS, Dhakal B, Hari P.

Case Rep Hematol. 2016;2016:2389038. Epub 2016 Oct 23.

Supplemental Content

Support Center